Henoch-Schönlein purpura following COVID-19 vaccine in a child: a case report-Reference-Cited by-同舟云学术

Henoch-Schönlein purpura following COVID-19 vaccine in a child: a case report

Published:2022-09-02 Issue:1 Volume:48 Page:
ISSN:1824-7288
Container-title:Italian Journal of Pediatrics
language:en
Short-container-title:Ital J Pediatr

Author:

Casini Francesca^ORCID,Magenes Vittoria Carlotta,De Sanctis Marina,Gattinara Maurizio,Pandolfi Marco,Cambiaghi Stefano,Zuccotti Gian Vincenzo,Fabiano Valentina

Abstract

Abstract Background Henoch-Schönlein purpura (HSP) is an IgA-mediated small vessel vasculitis, typical of childhood. It’s a self-limiting disease and it affects different systems. HSP is characterized by dermatological, abdominal, joint and renal clinical manifestations. This condition usually occurs upon infections, mainly upper respiratory tract ones, medications, vaccinations and malignancies. Case presentation We describe the case of a 11 year-old girl who developed a urticarial rash 12 days after the first dose of Pfizer-BioNTech BNT16B2b2 mRNA vaccine and a clear picture of Henoch Schönlein purpura 5 days after administration of the second dose of the same vaccine. Conclusion To our knowledge, this is the first description of a pediatric patient with Henoch-Schönlein purpura occurring in association with vaccination against COVID-19.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

https://link.springer.com/content/pdf/10.1186/s13052-022-01351-1.pdf

Reference17 articles.

1. Yang Y-H, Yu H-H, Chiang B-L. The diagnosis and classification of henoch-schönlein purpura: an updated review. Autoimmun Rev. 2014;13:355–8. https://doi.org/10.1016/j.autrev.2014.01.031.

2. Ruperto N, Ozen S, Pistorio A, Dolezalova P, Brogan P, Cabral DA, Cuttica R, Khubchandani R, Lovell DJ, O’Neil KM, et al. EULAR/PRINTO/PRES Criteria for Henoch-Schonlein Purpura, Childhood Polyarteritis Nodosa, Childhood Wegener Granulomatosis and Childhood Takayasu Arteritis: Ankara 2008. Part I: Overall Methodology and Clinical Characterisation. Ann Rheum Dis. 2010;69:790–7. https://doi.org/10.1136/ard.2009.116624.

3. The Italian Multicenter Study Group for Drug and Vaccine Safety in Children, Da Dalt L, Zerbinati C, Strafella MS, Renna S, Riceputi L, Di Pietro P, Barabino P, Scanferla S, Raucci U, et al. Henoch-Schönlein Purpura and drug and vaccine use in childhood: a case-control study. Ital J Pediatr. 2016;42:60. https://doi.org/10.1186/s13052-016-0267-2.

4. Mormile R, D’Alterio V, Treccagnoli G, Sorrentino P. Henoch-schonlein Purpura with Antiphospholipid antibodies after influenza vaccination: how fearful is it in children? Vaccine. 2004;23:567–8. https://doi.org/10.1016/j.vaccine.2004.07.029.

5. Kantor R, Galel A, Aviner S. Henoch-Schönlein Purpura post-influenza vaccination in a pediatric patient: a rare but possible adverse reaction to vaccine. Isr Med Assoc J IMAJ. 2020;22:654–6.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents: A Norwegian Nationwide Register-Based Study;2023-12-21

2. Year 2022: exploring COVID-19 pandemic in children;Italian Journal of Pediatrics;2023-09-29

3. Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination;Vaccine: X;2023-08

4. Henoch–Schönlein purpura with antecedent allergic diseases in a 4-year-old child: a case report;Annals of Medicine & Surgery;2023-05-08

5. Tozinameran;Reactions Weekly;2022-10-08